Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study
2020 · The Lancet · 418 citations
https://doi.org/10.1016/s0140-6736(20)31030-8
F
Francisco Abad‐Santos
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
402
Papers
6.5K
Citations
39
h-index
149
i10-index
Francisco Abad‐Santos is an academic researcher from Instituto de Salud Carlos III. The author has contributed to research in topics: Pharmacogenetics and Drug Metabolism & Pharmaceutical studies and practices & Psoriasis: Treatment and Pathogenesis. The author has an h-index of 39, co-authored 342 publications.
ORCID: 0000-0002-6519-8885Papers by this author
worksEffect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
2020 · Biomedicines · 110 citations
https://doi.org/10.3390/biomedicines8040094
Strategies to design clinical studies to identify predictive biomarkers in cancer research
2016 · Cancer Treatment Reviews · 102 citations
https://doi.org/10.1016/j.ctrv.2016.12.005
Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
2020 · Infectious Diseases and Therapy · 52 citations
https://doi.org/10.1007/s40121-020-00373-8
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers
2022 · Molecular Therapy — Nucleic Acids · 51 citations
https://doi.org/10.1016/j.omtn.2022.03.005
Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics
2020 · Advances in Therapy · 28 citations
https://doi.org/10.1007/s12325-020-01566-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat